Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-010063
Filing Date
2025-05-14
Accepted
2025-05-14 06:02:50
Documents
38
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 387508
2 EX-31.1 ex31-1.htm EX-31.1 8520
3 EX-31.2 ex31-2.htm EX-31.2 8479
4 EX-32.1 ex32-1.htm EX-32.1 5136
5 EX-32.2 ex32-2.htm EX-32.2 7448
  Complete submission text file 0001641172-25-010063.txt   2357472

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ladx-20250331.xsd EX-101.SCH 18129
7 XBRL CALCULATION FILE ladx-20250331_cal.xml EX-101.CAL 22578
8 XBRL DEFINITION FILE ladx-20250331_def.xml EX-101.DEF 100830
9 XBRL LABEL FILE ladx-20250331_lab.xml EX-101.LAB 173832
10 XBRL PRESENTATION FILE ladx-20250331_pre.xml EX-101.PRE 133630
40 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 263116
Mailing Address 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA 90049
Business Address 11726 SAN VICENTE BOULEVARD SUITE 650 LOS ANGELES CA 90049 310-826-5648
LadRx Corp (Filer) CIK: 0000799698 (see all company filings)

EIN.: 581642750 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15327 | Film No.: 25942473
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)